Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
MicroTech Medical (Hangzhou) Co., Ltd. Class H ( (HK:2235) ) has issued an update.
MicroTech Medical (Hangzhou) Co., Ltd. announced that its LinX continuous glucose monitoring system, the international brand name of AiDEX X, has received market approval in Brazil for use in both adults and children. Given Brazil’s status as a core Latin American market with about 16.62 million people living with diabetes and annual diabetes-related healthcare spending of roughly USD45.1 billion, this regulatory green light is expected to significantly enhance the company’s presence in the region, underpin the scaled expansion of its international business and support future revenue growth, though the company cautions that sales and income remain subject to market conditions.
The most recent analyst rating on (HK:2235) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on MicroTech Medical (Hangzhou) Co., Ltd. Class H stock, see the HK:2235 Stock Forecast page.
More about MicroTech Medical (Hangzhou) Co., Ltd. Class H
MicroTech Medical (Hangzhou) Co., Ltd. is a China-based medical technology company focused on diabetes monitoring, treatment and management solutions. Its core products include continuous glucose monitoring (CGM) systems, marketed internationally under the LinX (AiDEX X) brand, targeting both adult and pediatric patients in global markets, including emerging high-growth regions such as Latin America.
Average Trading Volume: 253,003
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.28B
Learn more about 2235 stock on TipRanks’ Stock Analysis page.